$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000107008123000011 Filed on February 21, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$220.4M	$167.4M	$698.8M
YoY Change	48.17%	1.32%	29.75%
Cost Of Revenue	$14.14M	$10.89M	$44.68M
YoY Change	39.56%	16.79%	38.2%
Gross Profit	$206.2M	$156.5M	$654.1M
YoY Change	48.8%	0.4%	29.21%
Gross Profit Margin	93.58%	93.49%	93.61%
Selling, General & Admin	$86.91M	$92.72M	$326.0M
YoY Change	18.62%	7.13%	14.08%
% of Gross Profit	42.14%	59.24%	49.84%
Research & Development	$195.1M	$188.7M	$651.5M
YoY Change	39.3%	25.93%	20.49%
% of Gross Profit	94.61%	120.56%	99.6%
Depreciation & Amortization	$42.83M	$38.87M	$128.8M
YoY Change	62.75%	106.61%	100.89%
% of Gross Profit	20.76%	24.83%	19.7%
Operating Expenses	$338.0M	$323.5M	$1.146B
YoY Change	43.67%	34.43%	25.54%
Operating Profit	-$117.6M	-$167.0M	-$447.4M
YoY Change	35.94%	97.05%	19.49%
Interest Expense	-$27.33M	-$39.70M	-$90.87M
YoY Change	16.23%	-4.11%	5.64%
% of Operating Profit
Other Income/Expense, Net	$9.956M	$50.35M	-$49.21M
YoY Change	-183.98%	-503.56%	-14.98%
Pretax Income	-$135.0M	-$189.7M	-$587.5M
YoY Change	10.75%	36.86%	13.34%
Income Tax	$3.969M	-$18.80M	-$28.47M
% Of Pretax Income
Net Earnings	-$139.0M	-$170.9M	-$559.0M
YoY Change	9.65%	19.28%	6.7%
Net Earnings / Revenue	-63.05%	-102.08%	-80.0%
Basic Earnings Per Share	-$1.88		-$7.79
Diluted Earnings Per Share	-$1.88	-$2.35	-$7.79
COMMON SHARES
Basic Shares Outstanding	73.82M	71.88M	71.73M
Diluted Shares Outstanding	73.73M		71.73M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$286.3M	$410.7M	$410.7M
YoY Change	-51.29%	-46.89%	-46.89%
Cash & Equivalents	$167.5M	$279.8M	$279.8M
Short-Term Investments	$118.8M	$130.9M	$130.9M
Other Short-Term Assets	$98.57M	$105.7M	$105.7M
YoY Change	232.49%	93.23%	93.23%
Inventory	$26.65M	$21.81M	$21.81M
Prepaid Expenses
Receivables	$201.9M	$155.6M	$155.6M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$613.4M	$693.8M	$693.8M
YoY Change	-20.75%	-27.3%	-27.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$79.49M	$72.59M	$175.0M
YoY Change	34.53%	38.04%	34.62%
Goodwill	$82.30M	$82.34M
YoY Change	0.0%	0.0%
Intangibles	$686.2M	$705.9M
YoY Change	-10.14%	-2.61%
Long-Term Investments
YoY Change
Other Assets	$47.88M	$48.58M	$48.58M
YoY Change	7.85%	4.48%	4.48%
Total Long-Term Assets	$995.4M	$1.012B	$1.012B
YoY Change	-2.94%	2.86%	2.86%
TOTAL ASSETS
Total Short-Term Assets	$613.4M	$693.8M	$693.8M
Total Long-Term Assets	$995.4M	$1.012B	$1.012B
Total Assets	$1.609B	$1.706B	$1.706B
YoY Change	-10.6%	-11.99%	-11.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.31M	$27.27M	$91.06M
YoY Change	43.27%	18.39%	295.32%
Accrued Expenses	$82.02M	$126.1M	$126.1M
YoY Change	3.15%	19.35%	19.35%
Deferred Revenue	$214.0K	$1.351M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$99.73M	$75.15M	$75.15M
YoY Change	-33.39%	-49.75%	-64.52%
Total Short-Term Liabilities	$441.6M	$406.2M	$406.2M
YoY Change	-7.37%	-20.24%	-20.24%
LONG-TERM LIABILITIES
Long-Term Debt	$572.1M	$571.7M	$1.276B
YoY Change	102.74%	102.81%	30.67%
Other Long-Term Liabilities	$141.0K	$2.641M	$267.5M
YoY Change	-99.95%	-99.16%	-14.68%
Total Long-Term Liabilities	$572.2M	$574.4M	$1.544B
YoY Change	102.79%	103.75%	19.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$441.6M	$406.2M	$406.2M
Total Long-Term Liabilities	$572.2M	$574.4M	$1.544B
Total Liabilities	$2.066B	$2.053B	$2.053B
YoY Change	9.32%	5.99%	5.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.796B	-$2.657B
YoY Change	25.68%	26.65%
Common Stock	$73.00K	$72.00K
YoY Change	2.82%	1.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$457.6M	-$347.1M	-$347.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.609B	$1.706B	$1.706B
YoY Change	-10.6%	-11.99%	-11.99%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$139.0M	-$170.9M	-$559.0M
YoY Change	9.65%	19.28%	6.7%
Depreciation, Depletion And Amortization	$42.83M	$38.87M	$128.8M
YoY Change	62.75%	106.61%	100.89%
Cash From Operating Activities	-$29.49M	-$166.0M	-$356.7M
YoY Change	-69.72%	141.09%	41.91%
INVESTING ACTIVITIES
Capital Expenditures	$10.27M	$8.622M	$32.02M
YoY Change	10.29%	-198.81%	13.48%
Acquisitions
YoY Change
Other Investing Activities	-$18.70M	$41.06M	$322.2M
YoY Change	-132.05%	-46.67%	30.24%
Cash From Investing Activities	-$28.97M	$32.44M	$290.2M
YoY Change	-159.07%	-52.49%	32.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.094M	302.9M	168.0M
YoY Change	250.51%	6857.23%	704.48%
NET CHANGE
Cash From Operating Activities	-29.49M	-166.0M	-356.7M
Cash From Investing Activities	-28.97M	32.44M	290.2M
Cash From Financing Activities	4.094M	302.9M	168.0M
Net Change In Cash	-62.33M	169.4M	98.71M
YoY Change	36.87%	4371.86%	-616.95%
FREE CASH FLOW
Cash From Operating Activities	-$29.49M	-$166.0M	-$356.7M
Capital Expenditures	$10.27M	$8.622M	$32.02M
Free Cash Flow	-$39.76M	-$174.6M	-$388.7M
YoY Change	-62.74%	190.42%	39.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	ptct	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2022Q4	ptct	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73104692
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70828226
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35969
CY2022	dei	Entity Registrant Name EntityRegistrantName	PTC THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3416587
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Corporate Court
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	South Plainfield,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07080
CY2022	dei	City Area Code CityAreaCode	908
CY2022	dei	Local Phone Number LocalPhoneNumber	222-7000
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	PTCT
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	2129532394
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73815144
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	279834000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189718000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	130871000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	583658000
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	155614000
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	110455000
CY2022Q4	us-gaap	Inventory Net InventoryNet	21808000
CY2021Q4	us-gaap	Inventory Net InventoryNet	15856000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	105658000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	54681000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	693785000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	954368000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72590000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52585000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	705891000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	724841000
CY2022Q4	us-gaap	Goodwill Goodwill	82341000
CY2021Q4	us-gaap	Goodwill Goodwill	82341000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102430000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77421000
CY2022Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	48582000
CY2021Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	46500000
CY2022Q4	us-gaap	Assets Assets	1705619000
CY2021Q4	us-gaap	Assets Assets	1938056000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	320366000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	288784000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	149540000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1351000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9370000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7273000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000000
CY2022Q4	ptct	Liability Sale Of Future Royalties Current LiabilitySaleOfFutureRoyaltiesCurrent	72149000
CY2021Q4	ptct	Liability Sale Of Future Royalties Current LiabilitySaleOfFutureRoyaltiesCurrent	59291000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1460000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	406236000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	509348000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	571722000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	281894000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	164000000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	239900000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	102834000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	137110000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100860000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73619000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18675000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20053000
CY2022Q4	ptct	Liability Sale Of Future Royalties Noncurrent LiabilitySaleOfFutureRoyaltiesNoncurrent	685737000
CY2021Q4	ptct	Liability Sale Of Future Royalties Noncurrent LiabilitySaleOfFutureRoyaltiesNoncurrent	674694000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2641000
CY2022Q4	us-gaap	Liabilities Liabilities	2052705000
CY2021Q4	us-gaap	Liabilities Liabilities	1936618000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73104692
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70828226
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	72000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	71000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2305020000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2123606000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4796000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24282000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2656974000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2097957000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-347086000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1438000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	380766000
CY2022	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	44678000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4922000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1705619000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1938056000
CY2021	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	32328000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	698801000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	538593000
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.64
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-559017000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7708000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523901000
CY2020	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	18942000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116554000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54751000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36892000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	651496000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	540684000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	477643000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	325998000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	285773000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	245164000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	25900000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	500000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-23280000
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	33384000
CY2020	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	10613000
CY2022	us-gaap	Operating Expenses OperatingExpenses	1146210000
CY2021	us-gaap	Operating Expenses OperatingExpenses	913036000
CY2020	us-gaap	Operating Expenses OperatingExpenses	812534000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-447409000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-374443000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-431768000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-90871000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-86022000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-56352000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-49207000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-57875000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	85188000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-587487000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-518340000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-402932000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28470000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5561000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35228000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-559017000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523901000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-438160000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71728634
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71728634
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70466393
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70466393
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66027908
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66027908
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.79
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.79
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.43
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.43
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.64
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-438160000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	108000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2502000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1145000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	28970000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	39177000
CY2022	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2022	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	36000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-51518000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-529939000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-487226000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-488533000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	594330000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28092000
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	42869000
CY2020	ptct	Stock Issued During Period Value Exchange Rights StockIssuedDuringPeriodValueExchangeRights	150528000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	70179000
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5303000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	70325000
CY2020	ptct	Adjustments To Additional Paid In Capital Receivable From Investor AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor	9107000
CY2020	us-gaap	Stockholders Equity Other StockholdersEquityOther	218000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-438160000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-50373000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	481982000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17309000
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5792000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	103513000
CY2021	ptct	Adjustments To Additional Paid In Capital Receivable From Investor AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor	483000
CY2021	us-gaap	Stockholders Equity Other StockholdersEquityOther	-25000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523901000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	36675000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1438000
CY2022	ptct	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	50000000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14632000
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	6450000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	110333000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-559017000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	29078000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-347086000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-559017000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523901000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-438160000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	128836000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	64134000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	43490000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	9884000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	7386000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6084000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	41382000
CY2022	ptct	Noncash Royalty Revenue Sale Of Future Royalties NoncashRoyaltyRevenueSaleOfFutureRoyalties	48738000
CY2021	ptct	Noncash Royalty Revenue Sale Of Future Royalties NoncashRoyaltyRevenueSaleOfFutureRoyalties	23460000
CY2020	ptct	Noncash Royalty Revenue Sale Of Future Royalties NoncashRoyaltyRevenueSaleOfFutureRoyalties	2055000
CY2022	ptct	Noncash Interest Expense Liability Related To Sale Of Future Royalties NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	72639000
CY2021	ptct	Noncash Interest Expense Liability Related To Sale Of Future Royalties NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	77683000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4985000
CY2020	ptct	Noncash Interest Expense Liability Related To Sale Of Future Royalties NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	31817000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	709000
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	33384000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4010000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8032000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-25900000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-500000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	23280000
CY2020	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	10613000
CY2020	ptct	Shares Issued Asset Acquisition SharesIssuedAssetAcquisition	42869000
CY2022	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	-3560000
CY2021	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	-6078000
CY2020	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	14310000
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-5740000
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-8281000
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	19252000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-7992000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1673000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-80000
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-16000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-34276000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	377000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5872000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1713000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-5299000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-409000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1901000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1848000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1020000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	110333000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	103513000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	70325000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	22598000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-13263000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-47391000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	56980000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-16887000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6668000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1800000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1841000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	51621000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	15310000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12621000
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	48468000
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	44991000
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	10483000
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	2913000
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	232000
CY2020	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	662000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	27542000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	45659000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	71963000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4558000
CY2022	ptct	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	-9600000
CY2020	ptct	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	-1165000
CY2022Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	0
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6704000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-3930000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1351000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-356654000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-251332000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	98707000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19094000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-79216000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197218000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-194071000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32016000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28213000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17843000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	52764000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	333148000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1439665000
CY2020	ptct	Payments To Acquire Convertible Debt Investment PaymentsToAcquireConvertibleDebtInvestment	10000000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22787000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	210018000
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	405234000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	843498000
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	944094000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	112958000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4281000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	120444000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	57118000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	38134000
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	100000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	290181000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	219182000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-561548000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14632000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17309000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	70179000
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	597000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28092000
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	11454000
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	300000000
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	150000000
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	28333000
CY2022	ptct	Payments On Deferred Consideration Obligation PaymentsOnDeferredConsiderationObligation	40400000
CY2020	ptct	Payments On Deferred Consideration Obligation PaymentsOnDeferredConsiderationObligation	38100000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	6450000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5792000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5303000
CY2022	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	1276000
CY2021	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	2224000
CY2020	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	17829000
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	50000000
CY2020	ptct	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	650000000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	167952000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20877000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	668715000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2772000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-7821000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7688000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	216312000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295528000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295925000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197218000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	216312000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	18463000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9588000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9802000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	26397000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	108000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2502000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1145000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35817000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	645000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	76811000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	41382000
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	33239000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	22294000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	14191000
CY2020	ptct	Stock Issued During Period Value Exchange Rights StockIssuedDuringPeriodValueExchangeRights	150528000
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	159000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	308000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1060000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC’s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes that this allows it to maximize value for all of its stakeholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has two products, Translarna™ (ataluren) and Emflaza<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged 2 years and older and in Russia for the treatment of nmDMD in patients aged two years and older. In July 2020, the European Commission approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. Translarna also has marketing authorization in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. The marketing authorization in the EEA was last renewed in June 2022 and is effective, unless extended, through August 5, 2023. In September 2022, the Company submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. The Company expects an opinion from the Committee for Medicinal Products for Human Use in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Translarna is an investigational new drug in the United States. Following the Company’s announcement of top-line results from the placebo-controlled trial of Study 041 in June 2022, the Company submitted a meeting request to the U.S. Food and Drug Administration (“FDA”) to gain clarity on the regulatory pathway for a potential re-submission of New Drug Application (“NDA”) for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support NDA re-submission. The Company recently had an informal meeting with the FDA, during which the Company discussed the potential path to an NDA re-submission for Translarna. Based on the meeting discussion, the Company plans to request an additional Type C meeting with the FDA in the near future to review the totality of data collected to date, including dystrophin and other mechanistic data as well as additional analyses that could support the benefit of Translarna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (“CNS”) including Upstaza (eladocagene exuparvovec) for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the European Commission approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. The Company is also preparing a biologics license application </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(“BLA”) for Upstaza for the treatment of AADC deficiency in the United States and it expects to submit a BLA to the FDA in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company holds the rights for the commercialization of Tegsedi<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (inotersen) and Waylivra<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Tegsedi-Waylivra Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). The Company began to make commercial sales of Tegsedi for the treatment of hATTR amyloidosis in Brazil in the second quarter of 2022 and it continues to make Tegsedi available in certain other countries within Latin America and the Caribbean through early access programs (“EAP Programs”). In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (“FCS”) in Brazil and the Company began to make commercial sales of Waylivra in Brazil in the third quarter of 2022 while continuing to make Waylivra available in certain other countries within Latin America and the Caribbean through EAP Programs. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy, or FPL. Waylivra has also received marketing authorization in the EU for the treatment of FCS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the European Commission in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020 and Japan in June 2021. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA and the Company expects the European Medicines Agency (“EMA”) to make a regulatory decision on approval for a label expansion for Evrysdi to include infants under two months old with SMA in 2023. In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. Enrollment in the Phase 2 study remains active and ongoing outside of the United States. Enrollment within the United States is paused as the FDA has requested additional data to allow the Phase 2 study to proceed; discussions are ongoing with the FDA to allow the resumption of U.S. enrollment. The Company expects data from the initial 12-week phase of the Phase 2 study in the <span style="background:#ffffff;">second quarter</span> of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company’s Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s Bio-e platform are vatiquinone and utreloxastat. The Company initiated a registration-directed Phase 2/3 placebo-controlled trial of vatiquinone in children with mitochondrial disease associated seizures in the third quarter of 2020. The Company has completed enrollment in this trial after previously experiencing delays in enrollment due to the COVID-19 pandemic. The Company anticipates results from the Phase 2/3 trial to be available in the second quarter of 2023. The Company also initiated a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in the fourth quarter of 2020 and anticipates results from this trial to be available in the second quarter of 2023. In the third quarter of 2021, the Company completed a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of utreloxastat. Utreloxastat was found to be well-tolerated with no </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reported serious adverse events while demonstrating predictable pharmacology. The Company initiated a Phase 2 trial of utreloxastat for amyotrophic lateral sclerosis in the first quarter of 2022 <span style="background:#ffffff;">and </span>enrollment is ongoing<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The most advanced molecule in the Company’s metabolic platform is sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products. The Company initiated a registration-directed Phase 3 trial for sepiapterin for PKU in the third quarter of 2021 with the primary endpoint in the study of achieving statistically-significant reduction in blood Phe level. The primary analysis population includes those patients who have a greater than 30% reduction in blood Phe levels during the Part 1 run-in phase of the trial. In January 2023, the Company announced preliminary data from the Part 1 run-in phase of this trial, including that the mean reduction in blood Phe levels in an initial cohort of subjects during the Part 1 would be recognized as clinically meaningful if maintained in Part 2 of the trial. The Company now expects results from Part 2 of this trial to be available in May 2023 as the trial is overenrolled and additional time is required for the entirety of the primary analysis population to complete the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unesbulin is the Company’s most advanced oncology agent. The Company completed its Phase 1 trials evaluating unesbulin in leiomyosarcoma (“LMS”) and diffuse intrinsic pontine glioma (“DIPG”) in the fourth quarter of 2021. The Company initiated a registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS in the first quarter of 2022 and enrollment is ongoing. The initiation of the Company’s registration-directed Phase 2/3 trial of unesbulin for DIPG was delayed as it continued to track the progress of patients in its Phase 1 trial and analyze the corresponding data. The Company now expects to initiate a registration-directed Phase 2/3 trial of unesbulin for the treatment of DIPG in the fourth quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of 2022, the Company had an accumulated deficit of approximately $2,657.0 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 (see Note 8), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, “at the market offering” of its common stock, its initial public offering of common stock in June 2013, proceeds from the Royalty Purchase Agreement dated as of July 17, 2020, by and among the Company, RPI 2019 Intermediate Finance Trust (“RPI”), and, solely for the limited purposes set forth therein, Royalty Pharma PLC (the “Royalty Purchase Agreement”) (see Note 2), net proceeds from our borrowings under our credit agreement with Blackstone (see Note 8), private placements of its convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. On August 15, 2022, the Company repaid the outstanding principal amount and accrued interest, totaling $152.3 million, of the 3.00% convertible senior notes due August 15, 2022 (the “2022 Convertible Notes”) that was due upon maturity in accordance with the terms of the notes. The Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017 and Upstaza for the treatment of AADC deficiency in the EEA since May 2022. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.</p>
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2657000000.0
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for the convertible notes, indefinite lived intangible assets annual impairment assessment, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2019Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	7500000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	23104000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	279834000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189718000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	16091000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	7500000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295925000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197218000
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	499000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22610000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company’s financial instruments that are exposed to credit risks consist primarily of cash and cash equivalents, available-for-sale marketable securities and accounts receivable. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company has not experienced any credit losses in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">these accounts and does not believe it is exposed to any significant credit risk on these funds. The Company’s investment policy includes guidelines on the quality of the financial institutions and financial instruments the Company is allowed to invest in, which the Company believes minimizes the exposure to concentration of credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its accounts receivable related to its product sales. The payment terms are predetermined and the Company evaluates the creditworthiness of each customer or distributor on a regular basis. The Company reserves all uninsured amounts billed directly to a patient until the time of cash receipt as collectability is not reasonably assured at the time the product is received. To date, the Company has not incurred any material credit losses.</p>
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1078000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1418000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14074000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	7721000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6656000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6717000
CY2022Q4	us-gaap	Inventory Net InventoryNet	21808000
CY2021Q4	us-gaap	Inventory Net InventoryNet	15856000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	1700000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2200000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	377287000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	107000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	709000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	376685000
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2020Q3	ptct	Assigned Royalty Payment Retained Percentage AssignedRoyaltyPaymentRetainedPercentage	0.57067
CY2022Q4	ptct	Revenue Recognition Milestone Potential Achievements RevenueRecognitionMilestonePotentialAchievements	250000000.0
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0
CY2022	ptct	Change In Taxable Income Change In Tax Code Qualifying Research And Development Costs ChangeInTaxableIncomeChangeInTaxCodeQualifyingResearchAndDevelopmentCosts	450100000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-16900000
CY2021Q4	ptct	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022Q4	ptct	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2022	us-gaap	Debt Securities Trading Realized Gain Loss DebtSecuritiesTradingRealizedGainLoss	4000000.0
CY2021	us-gaap	Debt Securities Trading Realized Gain Loss DebtSecuritiesTradingRealizedGainLoss	800000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	499000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10186000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	499000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	10186000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	673000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	256801000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20100000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	261786000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18700000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000000.0
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	12424000
CY2022Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	10186000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	221611000
CY2021Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	155074000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	109958000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	79758000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37368000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27173000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72590000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52585000
CY2022	us-gaap	Depreciation Depreciation	12300000
CY2021	us-gaap	Depreciation Depreciation	9400000
CY2020	us-gaap	Depreciation Depreciation	6600000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000000.0
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	25200000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4712000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1287000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	21400000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	15300000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	19804000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	16411000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	12368000000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	4557000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4361000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	2448000000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	808000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	656000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	450000000
CY2022	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	25169000
CY2021	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	21428000
CY2020	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	15266000000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y7M9D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y10M13D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0861
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0891
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P10Y3D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	14736000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	13683000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	8462000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1276000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2224000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	17829000
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1724000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	776000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	171000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35817000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	645000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	76811000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	41382000
CY2022Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	38882000
CY2021Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	26434000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3093000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3547000
CY2022Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	63787000
CY2021Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	61662000
CY2022Q4	ptct	Sales Rebates Current SalesRebatesCurrent	67355000
CY2021Q4	ptct	Sales Rebates Current SalesRebatesCurrent	68770000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	40546000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15373000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	18456000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20431000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	3000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	19985000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	3000000
CY2022Q4	ptct	Lessee Operating Lease Liability Payments Due Year Fiveand Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter	193792000
CY2022Q4	ptct	Finance Lease Liability Payments Due Year Five And After FinanceLeaseLiabilityPaymentsDueYearFiveAndAfter	18000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	268037000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	30000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	157807000
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	8325000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	110230000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	21675000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	62669000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55733000
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	35679000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27268000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	23033000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12054000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12639000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	320366000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	288784000
CY2020Q3	ptct	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	650000000.0
CY2020Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.110
CY2021Q4	ptct	Liability Sale Of Future Royalties LiabilitySaleOfFutureRoyalties	733985000
CY2022	ptct	Liability Sale Of Future Royalties Royalty Revenue Payable LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable	48738000
CY2022	ptct	Liability Sale Of Future Royalties Interest Expense LiabilitySaleOfFutureRoyaltiesInterestExpense	72639000
CY2022Q4	ptct	Liability Sale Of Future Royalties LiabilitySaleOfFutureRoyalties	757886000
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.087
CY2020	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	542470
CY2020Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	53.37
CY2020	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	28100000
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-559017000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-559017000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-523901000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-523901000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-438160000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-438160000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71728634
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71728634
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70466393
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70466393
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66027908
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66027908
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.79
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.79
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.43
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.43
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.64
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.64
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4000000.0
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1400000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14018753
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12292413
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10645735
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	110333000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103513000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70325000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	176100000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M8D
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1400000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	8208000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-591126000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-487726000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-452475000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3639000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-30614000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	49543000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-587487000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-518340000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-402932000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4224000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3844000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	24984000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1582000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1340000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4372000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-23689000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-10587000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	377000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5872000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28470000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5561000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35228000
CY2022Q4	ptct	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	52532000
CY2021Q4	ptct	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	87998000
CY2022Q4	ptct	Deferred Tax Assets Tax Credit Federal DeferredTaxAssetsTaxCreditFederal	174802000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0307
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0074
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0331
CY2022	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0183
CY2021	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0406
CY2020	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0666
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0589
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0450
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0493
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2336
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2903
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2640
CY2022	ptct	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsPercent	-0.0010
CY2021	ptct	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsPercent	0.1205
CY2020	ptct	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsPercent	0.0293
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0017
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0072
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0034
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0146
CY2021	ptct	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositionsPercent	0.0478
CY2020	ptct	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositionsPercent	0.0061
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0012
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0484
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0107
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0874
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	102834000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	137110000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	102834000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	137110000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2124000
CY2021Q4	ptct	Deferred Tax Assets Tax Credit Federal DeferredTaxAssetsTaxCreditFederal	142595000
CY2022Q4	ptct	Deferred Tax Assets Tax Credit State DeferredTaxAssetsTaxCreditState	9787000
CY2021Q4	ptct	Deferred Tax Assets Tax Credit State DeferredTaxAssetsTaxCreditState	8054000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	69957000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	76589000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	10316000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	9159000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	4837000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	3316000
CY2022Q4	ptct	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	110219000
CY2021Q4	ptct	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	241000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	27054000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15273000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	185589000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	148503000
CY2022Q4	ptct	Deferred Tax Assets Noncash Interest Expense DeferredTaxAssetsNoncashInterestExpense	30160000
CY2021Q4	ptct	Deferred Tax Assets Noncash Interest Expense DeferredTaxAssetsNoncashInterestExpense	26040000
CY2022Q4	ptct	Other Comprehensive Gain Loss Net OtherComprehensiveGainLossNet	-719000
CY2021Q4	ptct	Other Comprehensive Gain Loss Net OtherComprehensiveGainLossNet	143000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	676658000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	526119000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	672172000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	525570000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4486000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	549000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4486000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	549000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	102834000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	137110000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	107320000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	137659000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	102834000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	137110000
CY2022	ptct	Taxable Income Before Net Operating Loss TaxableIncomeBeforeNetOperatingLoss	61600000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4200000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	672200000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	525600000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	146600000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	146000000.0
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	145800000
CY2020	ptct	Operating Loss Carryforwards Utilized OperatingLossCarryforwardsUtilized	364100000
CY2021	ptct	Operating Loss Carryforwards Utilized OperatingLossCarryforwardsUtilized	0
CY2022	ptct	Operating Loss Carryforwards Utilized OperatingLossCarryforwardsUtilized	49300000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	ptct	Change In Taxable Income Change In Tax Code Qualifying Research And Development Costs ChangeInTaxableIncomeChangeInTaxCodeQualifyingResearchAndDevelopmentCosts	450100000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27200000
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2022Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	65100000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27217000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27217000
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q4	us-gaap	Assets Assets	1705619000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72590000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	698801000
CY2021Q4	us-gaap	Assets Assets	1938056000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52585000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	538593000
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	8400000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6600000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5300000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116600000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54800000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36900000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	142324000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	30609000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9352000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9352000
CY2022Q4	ptct	Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter	60688000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	252325000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	705891000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001070081-23-000011-index-headers.html	Edgar Link	pending
0001070081-23-000011-index.html	Edgar Link	pending
0001070081-23-000011.txt	Edgar Link	pending
0001070081-23-000011-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmb-20221231.xsd	Edgar Link	pending
tmb-20221231x10k.htm	Edgar Link	pending
tmb-20221231x10k006.jpg	Edgar Link	pending
tmb-20221231xex10d18.htm	Edgar Link	pending
tmb-20221231xex10d19.htm	Edgar Link	pending
tmb-20221231xex10d20.htm	Edgar Link	pending
tmb-20221231xex10d21.htm	Edgar Link	pending
tmb-20221231xex10d23.htm	Edgar Link	pending
tmb-20221231xex10d23001.jpg	Edgar Link	pending
tmb-20221231xex10d23005.jpg	Edgar Link	pending
tmb-20221231xex10d55.htm	Edgar Link	pending
tmb-20221231xex10d56.htm	Edgar Link	pending
tmb-20221231xex21d1.htm	Edgar Link	pending
tmb-20221231xex23d1.htm	Edgar Link	pending
tmb-20221231xex31d1.htm	Edgar Link	pending
tmb-20221231xex31d2.htm	Edgar Link	pending
tmb-20221231xex32d1.htm	Edgar Link	pending
tmb-20221231xex32d2.htm	Edgar Link	pending
tmb-20221231_cal.xml	Edgar Link	unprocessable
tmb-20221231_def.xml	Edgar Link	unprocessable
tmb-20221231_lab.xml	Edgar Link	unprocessable
tmb-20221231_pre.xml	Edgar Link	unprocessable
tmb-20221231x10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

2023 Q1 Form 10-K Financial Statement

#000107008123000011 Filed on February 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC THERAPEUTICS, INC. Stock $ptct

2023 Q1 Form 10-K Financial Statement

#000107008123000011 Filed on February 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct